Surufatinib for advanced neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of neuroendocrine neoplasm (a type of tumor that can grow in hormone-making cells).
- Your tumor must be measurable on a scan (like a CT or MRI).
- Your organs and bone marrow must be working well enough for treatment.
- You must be expected to live at least 12 more weeks.
- You cannot have other active cancers (except for certain skin, cervical, or breast cancers treated fully).
- You cannot have active bleeding, ulcers, uncontrolled high blood pressure, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests a combination of three drugs (surufatinib, serplulimab, and standard chemotherapy) as a first treatment for advanced solid tumors that have neuroendocrine differentiation. The goal is to see if this combination helps control the cancer better than standard therapy alone.
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
This study tests a new combination of two drugs (Surufatinib and Envolizumab) as a second treatment option for people with head and neck cancer that has returned or spread. It's for patients whose first treatment (usually chemo or immunotherapy) stopped working within 6 months.
This study tests a drug called surufatinib for people with neuroendocrine tumors. It aims to see how safe and effective the treatment is in real-world patients.
This study tests a pill called surufatinib after surgery to see if it can prevent neuroendocrine tumors from coming back. It is for patients with high-risk features like advanced stage or a higher grade of tumor.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.